MedPath

Brainsway

🇮🇱Israel
Ownership
-
Employees
106
Market Cap
-
Website
Introduction

Brainsway Ltd. engages in the development and sale of non-invasive neurostimulation treatments using the proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD). The Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.

Clinical Trials

20

Active:1
Completed:7

Trial Phases

6 Phases

Early Phase 1:1
Phase 1:2
Phase 2:4
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials

Not Applicable
10 (52.6%)
Phase 2
4 (21.1%)
Phase 1
2 (10.5%)
Early Phase 1
1 (5.3%)
Phase 3
1 (5.3%)
Phase 4
1 (5.3%)

New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD)

Not Applicable
Active, not recruiting
Conditions
Major Depressive Disorder
First Posted Date
2024-04-10
Last Posted Date
2025-04-08
Lead Sponsor
Brainsway
Target Recruit Count
104
Registration Number
NCT06357832
Locations
🇺🇸

Novus Neurology, Tuscaloosa, Alabama, United States

🇺🇸

Inland Psychiatric Medical Group, Inc., Redlands, California, United States

🇺🇸

DTMS Center LLC, Palm Beach, Florida, United States

and more 6 locations

Evaluation of the Long Term Efficacy and Durability of the BrainsWay Deep TMS in OCD Subjects

Not Applicable
Conditions
Obsessive-Compulsive Disorder
First Posted Date
2022-06-03
Last Posted Date
2022-07-20
Lead Sponsor
Brainsway
Target Recruit Count
124
Registration Number
NCT05404360

Brainsway DTMS for Treatment of MDD Using iTBS

Phase 4
Completed
Conditions
Major Depressive Disorder
First Posted Date
2020-12-22
Last Posted Date
2020-12-23
Lead Sponsor
Brainsway
Target Recruit Count
177
Registration Number
NCT04679753
Locations
🇨🇦

SynapseTMS, Yorkton, Saskatchewan, Canada

Combining H1-Coil Deep Transcranial Magnetic Stimulation (dTMS) and App-guided CBT in Subjects With Major Depression Disorder (MDD)

Conditions
Data Collection for Facilitation of Machine Learning Algorithm for Personalized Treatment
First Posted Date
2020-07-02
Last Posted Date
2020-07-09
Lead Sponsor
Brainsway
Target Recruit Count
540
Registration Number
NCT04455646
Locations
🇺🇸

Kadima Neuropsychiatry, San Diego, California, United States

🇺🇸

Advanced Mental Health Care Inc. - Juno Beach, Juno Beach, Florida, United States

🇺🇸

Advanced Mental Health Care Inc. - Palm Beach, Palm Beach, Florida, United States

and more 19 locations

Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)

Not Applicable
Conditions
Major Depressive Disorder (MDD)
First Posted Date
2017-01-06
Last Posted Date
2020-07-15
Lead Sponsor
Brainsway
Target Recruit Count
106
Registration Number
NCT03012724
Locations
🇺🇸

Kadima Neuropsychiatry, La Jolla, California, United States

🇺🇸

CalNeuro Research Group, Los Angeles, California, United States

🇺🇸

Advanced Mental Health Care Inc. - Juno Beach, Juno Beach, Florida, United States

and more 6 locations
  • Prev
  • 1
  • 2
  • 3
  • 4
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.